CIP
FATE icon

Chartwell Investment Partners’s Fate Therapeutics FATE Stock Holding History

Chartwell Investment Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,708
Closed -$685K – 427
2021
Q4 		$685K Sell
11,708
-207
-2% -$11.7K 0.02% 400
2021
Q3 		$706K Hold
11,915
– – 0.02% 398
2021
Q2 		$1.03M Buy
11,915
+6,305
+112% +$508K 0.03% 372
2021
Q1 		$463K Sell
5,610
-300
-5% -$28.7K 0.01% 401
2020
Q4 		$537K Buy
+5,910
New +$367K 0.02% 399
2018
Q3 		– Sell
-77,304
Closed -$877K – 480
2018
Q2 		$877K Sell
77,304
-2,943
-4% -$32.4K 0.03% 451
2018
Q1 		$783K Buy
+80,247
New +$769K 0.03% 382

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Chartwell Investment Partners's FATE Position: Q1 2022 in Review

Chartwell Investment Partners sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 11,708 shares — an estimated $685K sold.

Chartwell Investment Partners first reported a position in FATE in Q1 2018 and held it in 7 quarters. The position peaked at $1.03M in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Chartwell Investment Partners reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 11,708 Fate Therapeutics shares in Q1 2022, an estimated $685K.
  • Chartwell Investment Partners first reported a position in Fate Therapeutics in Q1 2018 and held it in 7 quarters.
  • Chartwell Investment Partners's Fate Therapeutics position peaked at $1.03M in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Chartwell Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.